Unfavorable effect of atropine-diphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea.
In this double-blind, randomized study, 200 normal subjects received a three-day course of one of five treatment regimens: lincomycin hydrochloride monohydrate injection (sterile solution, 300 mg/ml) with two tablets of either placebo, a mixture of atropine sulfate and diphenoxylate hydrochloride (Lomotil), an aspirin-phenacetin-caffeine (APC) combination or the latter with codeine, or an injection of saline with two placebo tablets. Gastrointestinal irritation was most prominent in subjects receiving lincomycin with atropine-diphenoxylate and lincomycin with APC plus codeine (P less than .05). Decreased intestinal motility from atropine-diphenoxylate or codeine may increase the contact time between the lincomycin (or its metabolites) or some developing toxic substances and the mucosal epithelium. The use of atropine-diphenoxylate or codeine in treating lincomycin-induced diarrhea may be questionable.
D000284:Administration, Oral; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced* / Q000188:drug therapy; D004157:Diphenoxylate / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007540:Isonipecotic Acids / Q000627:therapeutic use*; D008034:Lincomycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010615:Phenacetin / Q000627:therapeutic use; D010919:Placebos
D007540:Isonipecotic Acids; D010919:Placebos; D002110:Caffeine; D004157:Diphenoxylate; D008034:Lincomycin; D010615:Phenacetin; D001241:Aspirin